|
1
|
Smolle E, Taucher V, Pichler M, Petru E,
Lax S and Haybaeck J: Targeting signaling pathways in epithelial
ovarian cancer. Int J Mol Sci. 14:9536–9555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crallan RA, Georgopoulos NT and Southgate
J: Experimental models of human bladder carcinogenesis.
Carcinogenesis. 27:374–381. 2006. View Article : Google Scholar
|
|
3
|
You Q, Cai L, Zheng J, Tong X, Zhang D and
Zhang Y: Isolation of human mesenchymal stem cells from
third-trimester amniotic fluid. Int J Gynaecol Obstet. 103:149–152.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waldmann TA: The biology of interleukin-2
and interleukin-15: Implications for cancer therapy and vaccine
design. Nat Rev Immunol. 6:595–601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sereti I, Anthony KB, Martinez-Wilson H,
Lempicki R, Adelsberger J, Metcalf JA, Hallahan CW, Follmann D,
Davey RT, Kovacs JA, et al: IL-2-induced CD4+ T-cell expansion in
HIV-infected patients is associated with long-term decreases in
T-cell proliferation. Blood. 104:775–780. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tourani JM, Pfister C, Tubiana N, Ouldkaci
M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, et
al: Subcutaneous Administration Propeukin Program Cooperative
Group: Subcutaneous interleukin-2 and interferon alfa
administration in patients with metastatic renal cell carcinoma:
Final results of SCAPP III, a large, multicenter, phase II,
nonrandomized study with sequential analysis design - the
Subcutaneous Administration Propeukin Program Cooperative Group. J
Clin Oncol. 21:3987–3994. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang T, Wall EM, Milne K, Theiss P, Watson
P and Nelson BH: CD8+ T cells induce complete regression of
advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent
mechanism. Clin Cancer Res. 13:7172–7180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vlad AM, Budiu RA, Lenzner DE, Wang Y,
Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV and
Edwards RP: A phase II trial of intraperitoneal interleukin-2 in
patients with platinum-resistant or platinum-refractory ovarian
cancer. Cancer Immunol Immunother. 59:293–301. 2010. View Article : Google Scholar
|
|
9
|
Lee JM, Yoon SH, Kim HS, Kim SY, Sohn HJ,
Oh ST, Oh IH and Kim TG: Direct and indirect antitumor effects by
human peripheral blood lymphocytes expressing both chimeric immune
receptor and interleukin-2 in ovarian cancer xenograft model.
Cancer Gene Ther. 17:742–750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang TH, Mao CP, He L, Tsai YC, Liu K, La
V, Wu TC and Hung CF: Tumor-targeted delivery of IL-2 by NKG2D
leads to accumulation of antigen-specific CD8+ T cells in the tumor
loci and enhanced anti-tumor effects. PLoS One. 7:e351412012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le Page C, Génin P, Baines MG and Hiscott
J: Interferon activation and innate immunity. Rev Immunogenet.
2:374–386. 2000.
|
|
12
|
Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L,
Yin A, Xia Y, Sun B and Wang X: Human mesenchymal stem cells
overexpressing pigment epithelium-derived factor inhibit
hepatocellular carcinoma in nude mice. Oncogene. 29:2784–2794.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lynch HT, Casey MJ, Snyder CL, Bewtra C,
Lynch JF, Butts M and Godwin AK: Hereditary ovarian cancer:
Heterogeneity, molecular genetics, pathology, and management. Mol
Oncol. 3:97–137. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei S, Kryczek I, Edwards RP, Zou L,
Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, et al:
Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and
tumor trafficking in patients with ovarian carcinoma. Cancer Res.
67:7487–7494. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yong RL, Shinojima N, Fueyo J, Gumin J,
Vecil GG, Marini FC, Bogler O, Andreeff M and Lang FF: Human bone
marrow-derived mesenchymal stem cells for intravascular delivery of
oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res.
69:8932–8940. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Studeny M, Marini FC, Champlin RE,
Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived
mesenchymal stem cells as vehicles for interferon-beta delivery
into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
|
|
17
|
Ren C, Kumar S, Chanda D, Chen J, Mountz
JD and Ponnazhagan S: Therapeutic potential of mesenchymal stem
cells producing interferon-alpha in a mouse melanoma lung
metastasis model. Stem Cells. 26:2332–2338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bexell D, Scheding S and Bengzon J: Toward
brain tumor gene therapy using multipotent mesenchymal stromal cell
vectors. Mol Ther. 18:1067–1075. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Spaeth E, Klopp A, Dembinski J, Andreeff M
and Marini F: Inflammation and tumor microenvironments: Defining
the migratory itinerary of mesenchymal stem cells. Gene Ther.
15:730–738. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De Coppi P, Bartsch G Jr, Siddiqui MM, Xu
T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ,
et al: Isolation of amniotic stem cell lines with potential for
therapy. Nat Biotechnol. 25:100–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren C, Kumar S, Chanda D, Chen J, Mountz
JD and Ponnazhagan S: Therapeutic potential of mesenchymal stem
cells producing interferon-alpha in a mouse melanoma lung
metastasis model. Stem Cells. 26:2332–2338. 2008. View Article : Google Scholar : PubMed/NCBI
|
